Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis

[1] Jung KS(2012)Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study Respir Med 106 382-389

[2] Park HY(2016)Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East Asia Respirology 21 119-127

[3] Park SY(2015)Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies Respir Med 109 1155-1163

[4] Lee SD(2016)Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β Lancet 388 963-973

[5] Xie CM(2018)-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial N Engl J Med 378 1671-1680

[6] Yunus F(2018)Once-daily single-inhaler triple versus dual therapy in patients with COPD Lancet 391 1076-1084

[7] Siler TM(2018)Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial Lancet Respir Med 6 747-758

[8] Kerwin E(2017)Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial Pharm Pract (Granada) 15 943-770

[9] Sousa AR(2018)Network meta-analysis: a technique to gather evidence from direct and indirect comparisons Eur Respir J 52 1801586-428

[10] Donald A(2019)Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis Chest 155 758-126

[1] Jung KS(2012)Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study Respir Med 106 382-389

[2] Park HY(2016)Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East Asia Respirology 21 119-127

[3] Park SY(2015)Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies Respir Med 109 1155-1163

[4] Lee SD(2016)Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β Lancet 388 963-973

[5] Xie CM(2018)-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial N Engl J Med 378 1671-1680

[6] Yunus F(2018)Once-daily single-inhaler triple versus dual therapy in patients with COPD Lancet 391 1076-1084

[7] Siler TM(2018)Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial Lancet Respir Med 6 747-758

[8] Kerwin E(2017)Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial Pharm Pract (Granada) 15 943-770

[9] Sousa AR(2018)Network meta-analysis: a technique to gather evidence from direct and indirect comparisons Eur Respir J 52 1801586-428

[10] Donald A(2019)Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis Chest 155 758-126